Lutetium-177 DOTA complex (177Lu-DOTA)

DOTA-chelated lutetium-177 is a radiotherapeutic payload widely utilized in the field of theranostics for targeted cancer treatment [Hennrich & Eder, 2019]. It comprises the radioisotope Lutetium-177, which is a beta-emitting lanthanide, held within the macrocyclic chelating agent DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) [PubChem]. This complex is not a biological target itself but serves as the cytotoxic component of radiopharmaceuticals, typically conjugated to ligands that target specific receptors like Somatostatin Receptors (SSTR) or Prostate-Specific Membrane Antigen (PSMA) [FDA]. The beta radiation emitted by Lutetium-177 has a short range (mean 0.67 mm), which allows for the destruction of tumor cells while minimizing damage to surrounding healthy tissue [NIH]. Additionally, its low-energy gamma emission enables real-time imaging and dosimetry, making it a versatile tool in precision oncology [Hennrich & Eder, 2019]. The DOTA chelator provides high thermodynamic stability and kinetic inertness, preventing the release of free Lutetium-177 into the bloodstream [Stasiuk & Long, 2013]. Clinical applications include the treatment of gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancer [FDA].

Other names

177Lu-DOTADOTA-Lu-177Lutetium-177 tetraxetanLutetium-177 DOTA complexDOTA-chelated lutetium-177

Lutetium-177 emits beta particles (electrons) with a maximum energy of 0.497 MeV that cause ionizing radiation damage, specifically double-strand DNA breaks and oxidative stress, within a short radius (mean path length 0.67 mm) of the binding site [FDA, 2018; PubChem]. The DOTA chelator (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) forms a highly stable complex with the radioisotope, ensuring it remains sequestered and attached to the targeting ligand during systemic circulation [Hennrich & Eder, 2019; Stasiuk & Long, 2013].